MC1082: A Phase I/II Trial of Pomalidomide (CC-4047), Bortezomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 21 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 21 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 07 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.